Titan Biotech Limited (BOM:524717)

Market Cap	16.54B +404.3%
Revenue (ttm)	2.06B +31.8%
Net Income	298.85M +38.8%
EPS	7.23 +38.7%
Shares Out	41.32M
PE Ratio	55.37
Forward PE	n/a
Dividend	0.50 (0.12%)
Ex-Dividend Date	Sep 19, 2025

Volume	23,729
Open	394.75
Previous Close	390.70
Day's Range	390.75 - 407.00
52-Week Range	82.31 - 555.65
Beta	-0.50
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About Titan Biotech

Titan Biotech Limited engages in the manufacture and sale of biological products in India and internationally. It offers food ingredients, including hydrolyzed vegetable protein, yeast extract powder, calcium propionate powder, potassium sorbate, and calcium lactate; collagen and protein products, such as wheat hydrolysate protein, corn hydrolysate protein, bovine collagen peptide, collagen peptide, fish collage, undernatured chicken collagen type II, mucopolysaccharides, chicken protein isolate, soya protein isolate, and pea protein isolate; a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1992
• Employees: 467
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524717

Financial Performance

In fiscal year 2026, Titan Biotech's revenue was 2.06 billion, an increase of 31.79% compared to the previous year's 1.56 billion. Earnings were 298.85 million, an increase of 38.80%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 13, 2026

Data Sources Report a data error